Patent details

Basic Information

Publication number:

EP3889173

PCT Application Number:

Type:

European Patent Granted for LU

Legal Status:

In force

Application number:

EP202048666

PCT Publication Number:

First applicant's nationality:

Translation Language:

EPO Publication Language:

English

English Title of Invention:

OPTIMIZED FACTOR VIII GENE

French Title of Invention:

GÈNE DU FACTEUR VIII OPTIMISÉ

German Title of Invention:

OPTIMIERTES FAKTOR-VIII-GEN

SPC Number:

Dates

Filing date:

14/02/2014

Grant date:

05/07/2023

EP Publication Date:

06/10/2021

PCT Publication Date:

Claims Translation Received Date:

Translations Received Date (B1 EP Publication):

Translations Received Date (B2 EP Publication):

Translations Received Date (B3 EP Publication):

Publication date:

05/07/2023

EP B1 Publication Date:

05/07/2023

EP B2 Publication Date:

EP B3 Publication Date:

Lapsed date:

Expiration date:

14/02/2034

Renunciation date:

Revocation date:

Annulment date:

Owner

From:

28/06/2023

 

 

Name:

Bioverativ Therapeutics Inc.

Address:

225 Second Avenue, Waltham MA 02451, United States (US)

Agent

Name:

ARONOVA S.A.

From:

28/09/2023

Address:

PO Box 327, L-4004, ESCH-SUR-ALZETTE, Luxembourg (LU)

To:

Inventor

1

Name:

TAN, Siyuan

Address:

United States (US)

2

Name:

PETERS, Robert, T.

Address:

United States (US)

Priority

Priority Number:

201361765626 P

Priority Date:

15/02/2013

Priority Country:

United States (US)

Classification

IPC classification:

C07K 14/755;

Publication

European Patent Bulletin

Issue number:

202327

Publication date:

05/07/2023

Description:

Grant (B1)

Annual Fees

Annual Fee Due Date:

01/03/2027

Annual Fee Number:

14

Annual Fee Amount:

198 Euro

Expected Payer:

Last Annual Fee Payment Date:

29/01/2026

Last Annual Fee Paid Number:

13

Last Annual Fee Paid Amount:

180 Euro

Payer:

CPA GLOBAL THE IP PLATFORM

Filing date	Document type	Number of pages
28/09/2023	Power Of Attorney	1
28/09/2023	Outgoing Correspondence	1